Derek Athy
NanDio, Inc. is a cancer screening company that is commercializing novel technology to bring accurate and cost-effective molecular diagnostics to the point of care by enabling revolutionary cancer detection and treatment planning tests. NanDio is currently focused on addressing pancreatic cancer, a cancer that is difficult to detect in early stages, has no overly effective therapies to treat the disease, and has very poor survival outcomes.
Modern sequencing and detection technologies are often labor intensive, expensive, and typically last hours or days; NanDio’s novel detection process is able to discover microRNA (miRNA) sequences on a microfluidic chip quickly and accurately and at a much lower cost than traditional methods. This technology platform can be applied to identify miRNAs from a pancreatic cancer patient’s tumor biopsy that have prognostic significance, to then guide treatment decisions for pancreatic cancer patients, resulting in more effective therapies and higher survival rates.
Currently, NanDio is performing validation interviews with physician groups and oncology teams around the country, while further developing the technology’s capabilities. Additionally, the company management is currently raising a Seed round of funding and has recently been exploring opportunities with local funding groups.